Wegovy and Saxenda are FDA-approved prescription brands for weight management, but their active ingredients and injection routines differ. Wegovy contains semaglutide; Saxenda contains liraglutide. Comparing them by name alone obscures the most practical distinctions: weekly versus daily injections, labeled populations, clinical evidence and pharmacy product identity.
Unlike many obesity-drug comparisons, this pair has a direct randomized study in a defined population. STEP 8 compared weekly semaglutide 2.4 mg and daily liraglutide 3.0 mg, with lifestyle counseling, for 68 weeks in adults with obesity or overweight without diabetes. Its results do not establish an outcome for every age group, newer Wegovy formulation or available generic liraglutide presentation.
Buyers should start with the specific product that a clinician has prescribed, then verify its approved indication, handling, supply and insurance terms. Generic liraglutide developments warrant their own verification rather than assumptions that a generic labeled for one condition automatically replaces all Saxenda uses.
Wegovy’s conventional weight-management injection contains semaglutide, whereas Saxenda contains liraglutide. Both engage GLP-1 receptors but have different pharmacology, labeled schedules and product identities.
The separate Ozempic vs Victoza comparison covers diabetes-branded members of these ingredient families. It does not replace obesity-specific Wegovy–Saxenda interpretation.
STEP 8 provides a direct 68-week comparison of weekly injectable semaglutide 2.4 mg versus daily injectable liraglutide 3.0 mg in adults with obesity or overweight without diabetes. Estimated mean weight change was −15.8% versus −6.4%, respectively. This evidence is specific to those regimens and the trial population—not Wegovy pills, Wegovy HD or every generic liraglutide application.
Both drug families include products with distinct U.S. approvals. A generic liraglutide approval referencing Victoza for diabetes is not proof that its labeled use is Saxenda weight management. Before discussing a lower-cost substitution, compare the exact approved product, indication, injection pen and strength.
| Factor | Wegovy injection | Saxenda injection |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Injection routine | Weekly for standard presentation | Daily |
| Direct comparator study | STEP 8 semaglutide 2.4-mg arm | STEP 8 liraglutide 3.0-mg arm |
| Weight change in STEP 8 | −15.8% at week 68 | −6.4% at week 68 |
| Other forms | Wegovy pills and HD need separate consideration | Generic liraglutide approval is product-specific |
| Buying requirement | Exact prescription and licensed pharmacy | Exact prescription and licensed pharmacy |
Standard Wegovy injection is given weekly under its own pen instructions; Saxenda injection uses a daily schedule. Frequency can affect planning, device familiarity and refill timing but does not establish a winner for every patient.
Oral Wegovy tablets and Wegovy HD are distinct from the standard injection used in the older direct trial. A weekly-versus-daily summary cannot be copied onto the pill or HD presentation.
STEP 8 randomized 338 adults with obesity or overweight without diabetes to weekly semaglutide 2.4 mg, daily liraglutide 3.0 mg or placebo, alongside diet and activity counseling. The open-label active-drug comparison assessed weight change at week 68.
Mean estimated weight reduction was 15.8% with semaglutide and 6.4% with liraglutide (difference 9.4 percentage points). These are study averages in the specified population and regimens; they are not an individual forecast or a substitute for the products’ full safety labels.
Both medicines have weight-management labeling with restrictions involving age and clinical circumstances. Not every person asking for an alternative is eligible, and similar BMI language does not erase other product-specific requirements.
Eligibility must be reviewed by a licensed clinician, including contraindications, other medications, treatment goals and whether a person is seeking long-term management or a different clinical indication.
Gastrointestinal adverse events are common with both drug families, and both have boxed warnings related to thyroid C-cell tumors. Trial incidence depends on follow-up and reporting; it should not be reduced to an unsourced blanket safety claim.
The injection schedule and potential interactions deserve medical review. Do not combine Wegovy and Saxenda or independently convert from one to another based on a comparison table.
FDA has approved generic liraglutide products, including a generic corresponding to the Saxenda weight-management product. Approval of a particular generic has its own indication and labeling; it is not permission to assume unrestricted availability or price.
For exact approved product identities and legitimate pharmacy access, see generic liraglutide purchase guidance. A pharmacy should confirm the relevant FDA listing and prescription before filling.
A clinical discussion should begin with age eligibility, the precise obesity indication, previous tolerability and how a daily versus weekly injection fits the patient’s care plan. Direct trial averages are useful for the studied injections, but individual response, GI adverse effects and contraindications remain relevant.
A person who prefers a tablet should recognize that Wegovy now has an oral formulation, not interpret the STEP 8 outcome as evidence about the pill. The Wegovy form comparison addresses oral-versus-injection use, which STEP 8 did not test.
Suppose an online pharmacy lists generic liraglutide near Saxenda. The buyer should establish whether the exact generic FDA approval corresponds to the relevant prescription indication and whether the dispensing quantity matches the prescribed injection schedule. Do not assume a generic trade listing is an approved substitute merely because liraglutide appears in its name.
The Wegovy brand guide is the route to distinguish weekly injectable semaglutide from newer oral and HD presentations. For broader decisions including non-GLP-1 options, use the Wegovy alternatives hub rather than extrapolating STEP 8 to every obesity medication.
A clinician choosing Saxenda needs to identify liraglutide in the appropriate weight-management product and prescription, not simply any liraglutide injection. The FDA has approved various liraglutide generics with different reference products; it is essential to verify which original product and labeled indications an actual generic is approved against.
For a prescribed semaglutide weight-management form, refer to Wegovy access. For branded liraglutide, use Saxenda access; for alternatives that may have generic status, see generic liraglutide product checks. No automatic cross-brand dose swap follows.
A pharmacy should verify the actual Saxenda pen and its corresponding prescription or a specific FDA-approved generic referencing the weight-management product where applicable. A listing for liraglutide without an identifiable approval, labeled purpose or packaging is insufficient to guarantee a Saxenda-equivalent fill.
For Wegovy, distinguish ordinary weekly pens from oral tablets and HD, which have separate strengths and use contexts. This makes package verification materially different even when a comparison headline discusses only two injections.
Comparing average trial outcomes cannot determine which therapy a member’s plan will cover. Wegovy and Saxenda may carry different formulary conditions, eligibility and member cost; a “generic liraglutide” price may belong to a diabetes-reference product rather than the prescribed obesity use.
Use the same treatment-period basis for written prescription quotes and add any required clinician follow-up or supplies. Wegovy cost by form covers semaglutide offers, while Saxenda or its approved generic must be verified against their own dispensing and benefit records.
This page preserves the actual STEP 8 population and regimen rather than ranking all GLP-1 products. It is not an injection conversion guide.
This site may receive commercial referral compensation where disclosed; such arrangements do not establish clinical preference or drug availability.
No. Wegovy contains semaglutide, while Saxenda contains liraglutide.
Conventional Wegovy injection is weekly; Saxenda uses daily injections.
STEP 8 directly compared specific weekly semaglutide and daily liraglutide injection regimens.
At 68 weeks, mean body-weight changes were −15.8% and −6.4% in the studied semaglutide and liraglutide groups.
No. It studied subcutaneous formulations.
FDA has approved particular generic liraglutide products; verify each exact product and indication.
No. They are different drugs with distinct prescribed regimens.
Yes. Wegovy and Saxenda weight-management products are prescription medicines.
No. Compare full product price, supply, coverage and eligibility rather than dose frequency.